Moderna company claims that the third dose of the anti-coronavirus vaccine evokes a reliable response of antibodies to the action of Delta strain, which is infamous for its extreme contagiousness. CNBC reported that, citing a recent medical research conducted by the company.
"In a phase two trial, Moderna is testing a 50-microgram dose of three vaccine booster candidates in previously vaccinated individuals. The booster shots produced a promising immune response against three variants, including Delta, with antibody levels approaching those seen in previously unvaccinated people who received two 100-microgram doses", the outlet quoted Moderna.
The tests are still underway but the results already look promising.
The company added that the Delta variant will cause more outbreaks of intections - even in the vaccinated people. “While we see durable Phase 3 efficacy through 6 months, we expect neutralizing titers will continue to wane and eventually impact vaccine efficacy. Given this intersection, we believe dose 3 booster will likely be necessary prior to the winter season,” Moderna stated.